$-0.19 EPS Expected for Inovio Pharmaceuticals Inc (INO)

October 30, 2017 – By Max Morgan

Analysts await Inovio Pharmaceuticals Inc (NASDAQ:INO) to report earnings on November, 8. They expect $-0.19 EPS, up 32.14 % or $0.09 from last year’s $-0.28 per share. After $-0.13 actual EPS reported by Inovio Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 46.15 % negative EPS growth. The stock increased 3.74% or $0.21 on October 27, reaching $5.83. About 1.01M shares traded. Inovio Pharmaceuticals Inc (NASDAQ:INO) has declined 29.01% since October 30, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Inovio Pharmaceuticals Inc (NASDAQ:INO) Ratings Coverage

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals had 32 analyst reports since August 10, 2015 according to SRatingsIntel. Piper Jaffray maintained the stock with “Overweight” rating in Monday, August 10 report. The stock of Inovio Pharmaceuticals Inc (NASDAQ:INO) earned “Buy” rating by H.C. Wainwright on Friday, July 7. Maxim Group maintained Inovio Pharmaceuticals Inc (NASDAQ:INO) rating on Thursday, June 8. Maxim Group has “Buy” rating and $1200 target. H.C. Wainwright maintained Inovio Pharmaceuticals Inc (NASDAQ:INO) on Friday, June 2 with “Buy” rating. H.C. Wainwright maintained the shares of INO in report on Friday, September 22 with “Buy” rating. The firm has “Buy” rating given on Thursday, June 8 by H.C. Wainwright. The company was maintained on Thursday, July 27 by H.C. Wainwright. H.C. Wainwright maintained the shares of INO in report on Thursday, May 25 with “Buy” rating. The rating was maintained by Brean Capital on Monday, March 14 with “Buy”. The stock of Inovio Pharmaceuticals Inc (NASDAQ:INO) has “Buy” rating given on Tuesday, August 8 by Stifel Nicolaus.

Inovio Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The company has market cap of $526.02 million. The Company’s DNA immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It currently has negative earnings. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus.

More recent Inovio Pharmaceuticals Inc (NASDAQ:INO) news were published by: Nasdaq.com which released: “Inovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on …” on October 24, 2017. Also Globenewswire.com published the news titled: “Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T …” on October 16, 2017. Streetinsider.com‘s news article titled: “Inovio Pharma (INO) Says Positive Zika Vaccine Clinical Study Data Published …” with publication date: October 05, 2017 was also an interesting one.